Wei Zang Selected Research

LY3076226

12/2021

A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wei Zang Research Topics

Disease

4	Neoplasms (Cancer) 12/2021 - 05/2010
2	Infections 08/2014 - 02/2008
1	Carcinoma (Carcinomatosis) 12/2021
1	Embolism (Embolus) 12/2021
1	Cicatrix (Scar) 01/2021
1	Hyperplasia 01/2021
1	Wound Infection (Wound Infections) 01/2021
1	Necrosis 01/2021
1	Burns 01/2021
1	Fascioliasis 01/2013
1	Oligodendroglioma 05/2010
1	Astrocytoma (Pilocytic Astrocytoma) 05/2010
1	Glioma (Gliomas) 05/2010
1	Schistosomiasis (Bilharziasis) 02/2008
1	Cryptosporidiosis 06/2007

Drug/Important Bio-Agent (IBA)

1	LY3076226IBA 12/2021
1	Monoclonal AntibodiesIBA 12/2021
1	Immunoglobulin G (IgG)IBA 12/2021
1	Maytansine (Maitansine)IBA 12/2021
1	Immunoconjugates (Immunoconjugate)IBA 12/2021
1	Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)IBA 12/2021
1	CollagenIBA 01/2021
1	Messenger RNA (mRNA)IBA 12/2019
1	compound 18IBA 12/2019
1	Glutathione (Reduced Glutathione)IBA 11/2019
1	CellophaneIBA 08/2014
1	Pharmaceutical PreparationsIBA 01/2013
1	Platelet-Derived Growth Factor alpha ReceptorIBA 05/2010
1	VaccinesIBA 02/2008
1	AntigensIBA 06/2007

Therapy/Procedure

1	Length of Stay 01/2021
1	Operative Surgical Procedures 01/2021
1	Lasers (Laser) 11/2019
1	Photothermal Therapy 11/2019
1	Drug Therapy (Chemotherapy) 11/2019